Turkish Journal of Medical Sciences
Volume 51

Number 6

Article 34

1-1-2021

The evaluation of breast findings detected through different
visualisation techniques inacromegaly patients ? a retrospective
study
PINAR AKHANLI
SEMA HEPŞEN
BEKİR UÇAN
HAKAN DÜĞER
HAYRİ BOSTAN

See next page for additional authors

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
AKHANLI, PINAR; HEPŞEN, SEMA; UÇAN, BEKİR; DÜĞER, HAKAN; BOSTAN, HAYRİ; KIZILGÜL,
MUHAMMED; SENCAR, MUHAMMED ERKAM; and ÇAKAL, ERMAN (2021) "The evaluation of breast
findings detected through different visualisation techniques inacromegaly patients ? a retrospective
study," Turkish Journal of Medical Sciences: Vol. 51: No. 6, Article 34. https://doi.org/10.3906/
sag-2105-35
Available at: https://journals.tubitak.gov.tr/medical/vol51/iss6/34

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

The evaluation of breast findings detected through different visualisation
techniques inacromegaly patients ? a retrospective study
Authors
PINAR AKHANLI, SEMA HEPŞEN, BEKİR UÇAN, HAKAN DÜĞER, HAYRİ BOSTAN, MUHAMMED KIZILGÜL,
MUHAMMED ERKAM SENCAR, and ERMAN ÇAKAL

This article is available in Turkish Journal of Medical Sciences: https://journals.tubitak.gov.tr/medical/vol51/iss6/34

Turkish Journal of Medical Sciences
http://journals.tubitak.gov.tr/medical/

Research Article

Turk J Med Sci
(2021) 51: 3073-3081
© TÜBİTAK
doi:10.3906/sag-2105-35

The evaluation of breast findings detected through different visualisation techniques in
acromegaly patients — a retrospective study
Pınar AKHANLI*, Sema HEPŞEN, Bekir UÇAN, Hakan DÜĞER, Hayri BOSTAN,
Muhammed KIZILGÜL, Muhammed Erkam SENCAR, Erman ÇAKAL
Department of Endocrinology and Metabolism, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and
Research Hospital, Ankara, Turkey
Received: 03.05.2021

Accepted/Published Online: 16.09.2021

Final Version: 00.00.2021

Background/aim: It is known that the increased growth hormone (GH) and insulin-like growth factor-1 (IGF-1) have mitogenic
and antiapoptotic properties in breast cells in acromegaly. Our study aims to evaluate breast findings in patients with acromegaly by
comparing them to the control group.
Materials and methods: Sixty-one patients followed with acromegaly diagnosis and 180 healthy controls were included in our study.
Demographic data, laboratory results, Breast Imaging-Reporting and Data System (BI-RADS) scores, and breast density evaluated via
mammography, malign and benign breast lesions evaluated via mammography, breast ultrasonography (USG), and breast magnetic
resonance imaging (MRI) of patients were compared to the control group.
Results: While BI-RADS scores were similar in patient and control groups, breast density in acromegaly patients was found out to be
higher compared to the control group (p = 0.754, p = 0.001, respectively). In acromegaly patients, the breast calcification rate was higher
than controls (p = 0.021). t was observed that mass frequency in USG in acromegaly patients increased when GH level increased as well
(p = 0.021). No difference was detected between benign and malign breast lesions diagnosed histopathologically (p = 0.031, p = 0.573,
respectively). There was not any difference in terms of BI-RADS scores, breast types, and breast lesions in acromegaly patients that were
in remission and not in remission (p > 0.05).
Conclusion: Benign and malign breast lesions were found out to be similar to the control group, although breast density rate was
detected to be higher in acromegaly patients. A regular follow-up is required in these patients via suitable breast visualization techniques
considering their age and clinical status due to mass formation risk derived from increased GH level and extreme breast density despite
the absence of any detected breast lesion frequency in acromegaly patients.
Key words: Acromegaly, breast density, breast neoplasm, breast cancer

1. Introduction
Acromegaly is a rare disorder, which progresses depending
on an increase in GH secretion and is derived from a
pituitary adenoma in general [1]. The estimated incidence
is nearly 4 cases per million/year in the general world
population and the prevalence 85 per million [2]. It is
reported that the mean age of diagnosis for acromegaly
is between 40 and 50 [3]. When growth hormone (GH)
secretion is high, it stimulates the hepatic secretion of
insulin-like growth factor-1 (IGF-1), which causes the
majority of acromegaly clinical symptoms [4]. Patients can
apply to a hospital with comorbidities related to extreme
GH or IGF-1 levels such as diabetes or glucose intolerance,
hypertension, obstructive sleep apnea syndrome,
cardiomyopathy, and goiter [3]. An increase in morbidity

and mortality rates depending upon cardiovascular,
cerebrovascular, and metabolic complications secondary
to acromegaly has been shown. It is considered that high
GH and IGF-1 levels can lead to cancer incidence increase
in acromegaly patients due to mitogenic and antiapoptotic
properties [5,6]. The increased risk of benign and
malignant tumors in acromegaly patients keeps on being a
matter of debate. Ultrasonography (USG), mammography,
and magnetic resonance imaging (MRI), when required,
are used to detect breast lesions in general. Breast
density is also evaluated via mammography in addition
to lesions. Immense breast tissue in mammography can
affect the risk of breast cancer. Although breast lesions
are generally benign, they can also be precancerous and
malignant. Breast cancer is the most common cancer type
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seen in females and comes after lung cancer in cancer
mortality [7]. Several research revealed that GH has an
important role on breast cell oncogenic transformation
and progression as both in vitro and in vivo [8]. While
an association between acromegaly and breast cancer in
several studies is revealed [2,9], this association cannot be
indicated in some others [10,11].
Our study aims to compare benign and malign breast
lesions, Breast Imaging-Reporting and Data System (BIRADS) scores, and breast density in acromegaly patients
retrospectively with control group through mammography,
USG, and MRI.
2. Material and methods
2.1. Study design
This study was designed as a retrospective study. The
Ethics Committee of our institute approved this study
regarding the principles of the Declaration of Helsinki.
Written informed consent was taken from subjects before
taking part in the study.
2.2. Patients and laboratory tests
Sixty-one female patients diagnosed with acromegaly
were followed and treated in Ankara Dışkapı Training and
Research Hospital Endocrinology and Metabolic Diseases
Department between 2008 and 2019 were compared to
180 female controls who accept to be part of our study.
Acromegaly diagnosis and active disease definition were
determined utilizing clinical findings, GH levels, GH
suppression below 1 g/L during oral glucose tolerance test
(OGTT), increased IGF-1 levels regulated according to age
and sex, and follow-up findings after surgery [9]. IGF-1 and
GH values of acromegaly patients measured in 3 months
before breast imagings of patients were recorded. Multiple
endocrine neoplasia (MEN) patients were excluded from
the study. The information related to chronic diseases of
patients was obtained from hospital records. Demographic
features of patients, laboratory test results, mammography,
breast USG, and MRI results were recorded. BI-RADS
scores and breast densities determined by mammography
(A, B, C, D according to BI-RADS density classification)
[10], benign calcification, macrocalcification, and
microcalcification presence, asymmetric density,
intramammary lymph node, and images that resemble a
mass as well as BI-RADS scores determined by only MRI
were also recorded. Mammography was based on for BIRADS scores in patients having both mammography
and MRI. Fibrocystic breast pattern, ductal ectasia,
fibroadenoma, apse, images compatible with hamartoma,
cystic and solid lesions determined by USG were recorded
in detail. Biopsy results of recorded lesions, if they were
carried out, were recorded. The malign lesion diagnosis of
patients were based on histopathologic diagnosis.
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Control group was composed by scanning retrospective
breast workups belonging to routine breast examinations
performed in Ankara Dışkapı Training and Research
Hospital Internal Diseases Department between 2018 and
2019. Consents of the controls were taken by calling them.
More than one doctor in the mammography unit in our
clinic evaluated radiological findings. We evaluated the
results of the patients retrospectively through the system.
The first workouts of patients were based on. Those
patients who are followed-up for any breast pathology
were excluded from the study.
2.3. Statistical analysis
Statistical analyses were performed using the SPSS software
version 21 (Chicago, IL). The variables were investigated
through visual (histograms, probability plots) and analytic
methods (Kolmogorov–Smirnov/Shapiro–Wilk’s test)
to determine whether they were normally distributed
or not. While the Student’s t-test was used to compare
tumor size detected with USG, the Mann–Whitney U
test was performed to compare other variables between
groups. Categorical data were presented as numbers and
percentages (%). Descriptive analyses were presented
using means and standard deviations for normally
distributed variables, whereas medians and interquartile
ranges (IQR) are at the 25th and 75th percentiles for
non-normally distributed variables. The proportions of
mammography and USG findings of patients in remission
or not were presented by using cross-tabulations. The Chisquare test or Fisher’s exact test, where appropriate, was
used to compare these proportions. A p-value, less than
0.05 was considered to show a statistically significant
difference. While investigating the associations between
breast findings and other variables, correlation coefficients
and their significance were calculated using the Spearman
test.
3. Results
Sixty-one female acromegaly patients and 180 female
controls were included in the study. Median ages of
patients and controls were 53 (IQR 25-75; 45-59) and 48
(IQR 25-75; 41-55), respectively. Total disease duration
of acromegaly patients was 7 (IQR 25-75; 2.5-11) years.
While median IGF-1 level of patients at the diagnosis time
was 655 (IQR 25-75; 528-901) ng/mL, median GH level
was 6.3 (IQR 25-75; 3.6-10) ng/mL. IGF-1 and GH values
of the patients measured on the closest date to the period
at which imaging methods were performed were 201
(IQR 25-75; 116.5-321.5) and 0.8 (IQR 25-75; 0.14-2.21),
respectively. Calculated IGF-1 values according to age and
gender at the diagnosis time of 53 (86.9%) patients were
higher than 97th percentile, 7 (11.5%) were between 90th
and 95th percentile, and 1 (1.6%) was between 90th and
95th percentile. There were macroadenoma in 48 (78.7%)
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patients and microadenoma in 13 (21.3%) patients. The
mean tumor size was 14.5 (11-20) mm. Hypertension
(37.7%), diabetes mellitus (34.4%), and coronary artery
disease (6.6%) were additional diseases in the acromegaly
group. TN/TS surgery was performed on 54 (88.5%)
patients as an initial treatment. The number of patients
who received an additional treatment after surgery was
as follows: 20 (32.8 %) patients- octreotide, 12 (19.7%)
patients- lanreotide, 6 (9.8%) patients- cabergoline in
addition to somatostatin analog treatment, 1 (1.6%)
patient- pegvisomant treatments. In addition to these
data, radiotherapy and gamma knife were performed on 2
(3.3%) and 5 (8.2%) patients, respectively, as an additional
treatment. Table 1 shows baseline characteristics, treatment
details, and laboratory test results of the subjects.

Considering the techniques performed on the patients
in the acromegaly group and on the subjects in the control
group, the data were as follows respectively: 32 (52.5%)
patients and 43 (23.9%) subjects- mammography, 10
(16.4%) patients and 43 (23.9%) subjects- USG, 1 (1.6%)
patient and 4 (2.2%) subjects- MRI, and 18 (29.5%) patients
and 87 (48.3%) subjects- both USG and mammography.
Moreover, in the control group, 1 subject (0.6%) was
performed both mammography and MRI, 1 subject (0.6%)
was performed both USG and MRI, and 1 subject (0.6%)
was performed USG, MRI, and mammography.
BI-RADS scores were similar in the patient and control
groups (p = 0.580). A significant difference was detected
among breast types showed by mammography between the
acromegaly and control groups (p = 0.001). Calcification

Table 1. Baseline characteristics, treatment details, and laboratory test results of the subjects.
Acromegaly patients

Controls

Number, n

61

180

Age, years

53 (45–59)

48 (41–55)

Active disease, n (%)

21 (34.4%)

Total disease duration, years

7 (2.5–11)

Macroadenoma, n (%)

48 (78.7)

Tumor size, mm

14.5 (11–20)

IGF-1, baseline (ng/mL)

655 (528–901)

-

GH, baseline (ng/mL)

6.3 (3.6–10)

-

IGF-1, measured on the closest date to the visualisation techniques
performed, (ng/mL)

201 (116.5–321.5)

GH, measured on the closest date to the visualisation techniques
performed, (ng/mL)

0.8 (0.14–2.21)

p value

Demographic data and laboratory test results
0.067

-

Treatment
Surgery, n (%)

54 (88.5)

Octreotide, n (%)

20 (32.8)

Lanreotide, n (%)

12 (19.7)

Pegvisomant, n (%)

1 (1.6)

Cabergoline, n (%)

6 (9.8)

Gama knife, n (%)

5 (8.2)

Radiotheraphy, n (%)

2 (3.3)

Comorbidities
Hypertension, n (%)

23 (37.7)

42 (23.3)

0.029

Diabetes mellitus, n (%)

21 (34.4)

43 (23.9)

0.108

Heart failure, n (%)

0 (0)

2 (1.1)

0.409

CAD, n (%)

4 (6.6)

5 (2.8)

0.179

IGF-1: Insulin-like growth factor, GH: Growth hormone, CAD: Coronary artery disease.
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presence was detected in 45 (90%) acromegaly patients and
101 (74.3%) subjects in the control group. Calcification
rate was higher in acromegaly patients than control
group (p = 0.021). The number of benign calcification,
microcalcification, and macrocalcification was 38 (84.5%),
6 (13.3%), and 1 (2.2%) in the acromegaly group and
91 (90.1%), 10 (9.9%), and 0 (0%) in the control group,
respectively. The presence of asymmetric density was
similar in the patient and control groups (p = 0.423). The
presence of intramammary lymph node in mammography
was also similar in both groups (p = 0.276). There was no
difference in mass frequency detected in mammography
between the two groups (p = 0.187). Cystic and solid masses
were 0 (0%) and 2 (100%) in acromegaly patients whereas
7 (38.9%) and 11 (61.1%) in the control group, respectively.
Similarly, there was no difference in mass frequency
detected in USG in both groups (p = 0.103). While cystic
and solid masses detected in USG in acromegaly patients
were 7 (70%) and 3 (30%) respectively, and they were 39
(66.1%) and 20 (11.1%) in the control group.The presence

of ductal ectasia and fibrocystic breast were similar in both
groups (p = 0.223, p = 0.226; respectively). The presence
of intramammary lymph nodes in USG was also similar
in two groups (p = 797). Table 2 and 3 show breast lesions
of the patients detected via mammography and USG,
respectively. Breast cancer frequency detected in both
groups was similar (p = 0.573). There was no patient with
any benign breast lesions in the acromegaly patients,
however, there were 13 (7.2%) patients in the control group
(p = 0.031). In the acromegaly group, 2 (66.7%) patients
were with invasive ductal and 1 (33.3%) patient was with
mucinosis breast cancer. In the control group, on the other
hand, 1 (16.7%) patient was with ductal carcinoma in situ
(DCIS), 1 (16.7%) patient was with lobular carsinoma
in situ (LCIS), and 4 patients (66.7%) were with invasive
ductal carcinoma. Any acromegaly patient as not
diagnosed with breast cancer before acromegaly diagnosis.
Details belonging to histopathological findings of malign
and benign breast lesions are shown in Table 4. There was
no detected lesion in MRI in the patient group, however,

Table 2. Breast lesions in mamography of the subjects
Acromegaly patients

Controls

p value

BIRADS Score

2 (2-2)

2(2-2)

0.754

BIRADS 0 Score, n (%)

3 (6)

8 (5.9)

BIRADS 1 Score, n (%)

3 (6)

13 (9.6)

BIRADS 2 Score, n (%)

36 (72)

84 (61.8)

BIRADS 3 Score, n (%)

5 (10)

25 (18.4)

BIRADS 4 Score, n (%)

1 (2)

4 (2.9)

BIRADS 5 Score, n (%)

2 (4)

2 (1.5)

Breast density

0.001

A type, n (%)

2 (4)

16 (11.8)

B type, n (%)

18 (36)

74 (54.4)

C type, n (%)

29 (58)

45 (33.1)

D type, n (%)

1 (2)

1 (0.7)

Calcifications, n (%)

45 (90)

101 (74.3)

Benign, n (%)

38 (84.5)

91 (90.1)

Micro, n (%)

6 (13.3)

10 (9.9)

Macro, n (%)

1 (2.2)

0 (0)

Asymetric density, n (%)

21 (42)

40 (35.4)

0.423

Breast lesions

3 (6.3)

18 (13.4)

0.187

Cystic, n (%)

0 (0)

7 (38.9)

Solid, n (%)

3 (100)

11 (61.1)

Tumor size, mm

20 ± 8

19.4 ± 6.1

0.878

IMLN

5 (9.1)

20 (15)

0.276

0.021

BIRADS: Breast Imaging-Reporting and Data, IMLN: Intramammary lymph node.
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Table 3. Breast lesions in ultrasonography of the subjects.
Acromegaly patients
(n = 61)

Controls
(n = 180)

Patients with breast ultrasonography, n (%)

49 (81.7)

132 (73.3)

Breast lesions, n (%)

10 (27.8)

59 (42.8)

Cystic, n (%)

7 (70)

39 (66.1)

Solid, n (%)

3 (30)

20 (11.1)

Tumor size, mm

10.5 (4.7–15.5)

10 (5-18)

0.925

Ductal ectasia, n (%)

2 (3.3)

14 (7.9)

0.223

Fibrocystic breast, n (%)

2 (3.3)

14 (7.9)

0.226

IMLN, n (%)

3 (6.8)

8 (5.8)

0.797

p value

0.103

IMLN: Intramammary lymph node.
Table 4. Details belonging to histopathological findings of malign and benign breast
lesions.
Acromegaly
patients

Controls

p value

Malign, n (%)

3 (4.9)

6 (3.3)

0.573

DCIS, n (%)

0 (0)

1 (16.7)

LCIS, n (%)

0 (0)

1 (16.7)

İnvasive ductal carcinoma, n (%)

2 (66.7)

4 (66.7)

İnvasive lobular carcinoma, n (%)

0 (0)

0 (0)

Mucinous carcinoma, n (%)

1 (33.3)

0 (0)

Benign, n (%)

0 (0)

13 (7.2)

Fibroadenoma, n (%)

0 (0)

38.5

Hamartoma, n (%)

0 (0)

15.4

Abscess, n (%)

0 (0)

15.4

Lipoma, n (%)

0 (0)

30.8

0.031

DCIS: ductal carcinoma in situ LCIS: lobular carcinoma in situ.

1 patient was detected with two solid lesions on the right
and left (the biggest one was 11 mm) in the control group.
When acromegaly patients were evaluated, no
correlation was observed between BI-RADS scores and
breast density and age, disease duration, GH, and IGF1 levels (p > 0.05 for each). It was observed that mass
frequency in USG in acromegaly patients increased when
GH level increased as well (p = 0.021). The presence of
fibrocyst decreased acromegaly patients depending upon
age increase (p = 0.018, p = 0.072, respectively). There
was no correlation between calcification, intramammary
lymph node, ductal ectasia, mass presence detected
in mammography and breast cancer, and age, disease
duration, GH, and IGF-1 levels (p > 0.05 for each). 40
(65.6%) patients were in remission in the period of workup,

however 21 (34.4%) patients were not. Median IGF-1 and
GH in the period of workup were 201 (IQR 25-75; 118323) and (IQR 25-75; 0.14-2.16) ng/mL, respectively. BIRADS scores and breast types were similar in patients
in remission and not (p = 0.527, p = 0.754, respectively).
Median BI-RADS of patients in remission was observed as
2 (IQR 25-75; 2-2), and this rate was 2 (IQR 25-75; 1.25-2)
for patients not in remission. A mass was detected through
mammography in 1 (2.8%) and 2 (16.7 %) patients who
were in remission and not, respectively (p = 0.089). There
was no difference in asymmetric density rate between
patients in remission and not (p = 0.490). The number
of the patients being in remission and not in remission
and detected calcification through mammography was 36
(94.7%) and 9 (75%), respectively (p = 0.049).
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The presence of mass detected through USG was
observed in 6 (28.6%) patients in remission and in 4
(26.7%) patients not in remission (p = 0.924). There was
also no difference in fibrocyst and ductal ectasia rate
detected through USG between the patients who were
in remission and not in remission (p = 0.614, p = 0.313,
respectively). Breast cancer was detected in 1 (2.5%) and
2 (9.5%) patients being in remission and not, respectively.
4. Discussion
This study revealed that there was no difference in benign
and malign breast lesions between acromegaly patients and
the control group. When compared acromegaly patients
in remission to the patients who were not in remission,
similarly, no difference was found out. Besides, breast
density in acromegaly patients was detected to be higher
than the control group. It was also revealed when the GH
level increased, mass frequency in USG increased.
It is difficult to analyse breast lesions in acromegaly
patients due to the fact that acromegaly is a rare disease.
Extreme breast density in mammography can affect breast
cancer risk. Extreme tissue can make detecting small lesions
difficult by reducing the sensitivity of mammography
[11,12]. In addition to this, increased density is an
independent risk factor of breast cancer because the vast
majority of cancer progresses in glandular parenchyma
[13]. Breast density in mammography can show a change
according to the operator [14]. Mammographic density
is not related to breast firmness or breast size [15]. Breast
density is higher in young women and differs according
to genetic factors, estrogen using, climacteric, parity, and
tamoxifen using [16].
In our study BI-RADS scores were similar the patient
and control groups, however, breast density showed via
mammography was significantly high in acromegaly
group. We did not detect any correlation between BIRADS scores, breast density and age, disease duration,
GH, and IGF-1 levels.
According to a report published by Tacliafico et al., BIRADS scores and breast density of females with acromegaly
were significantly high when 30 premenopausal patients
with acromegaly compared to 60 premenopausal controls.
A positive correlation was found out between IGF-1 levels
and disease duration and mammographic breast density
[17].
In contrast with this study, an association between
IGF-1, seven subgroups of IGFBP and volumetric density
measures and area density measures was researched in a
study conducted by Hada et al with 293 females between
40 and 45 years. While new positive correlations between
IGFBP-2 and breast density percentage were detected, no
positive correlation was detected between IGF-1, IGFBP3
and breast density [18]. No postmenopausal patient to be
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included in our study could be the reason why BI-RADS
scores are similar with the control group and why there
is no correlation among GH, IGF-1 levels and disease
duration, age factor, and mammographic breast density.
As far as we know, there are many studies evaluating
malign breast lesions in females with acromegaly, however
there are not any studies evaluating benign breast lesions
in literature. Up to now, there has not been a detailed
study analyzing both benign and malign breast lesions in
literature, without our study.
We revealed that calcification rate was significantly
higher in females with acromegaly than the control group
when breast lesions were evaluated.
According to a report published by Stompel et al, with
29% of females between 45-49, 34% between 50-54, and
43% between 55-59 years were with benign calcification
[16]. In our study, benign calcification rate of acromegaly
patients was 84%, which is higher than studies in literature.
In addition to that, we did not detect increased benign and
malign lesion frequency in the patient group compared
to the control group. Asymmetric density detected via
mammography, fibrocystic disease and ductal ectasia
detected via USG, intramammary lymph node detected
via both mammography and USG were similar in both
groups. In literature, there is no clear datum related to the
prevalence of breast lesions in acromegaly patients.
The upper limit of normal IGF-1 is associated with high
breast, prostate, colorectal, and lung cancer risk in general
population [4]. GH affects mammary gland growth and
lactation period. It shows this effect with not only by itself
but also with estrogen and progesterone. The effect of GH
on breast cancer cells can be through IGF-1 or proliferative
effect independent from IGF-1. Higher GHR, IGF-1,
and IGF-1R expression are observed on breast cancer
cells in humans. GH tumor expression is associated with
metastatic breast cancer and poor prognosis positively
[19]. The proportion of malign lesion in the patient group
was not found out to be higher than the control group.
Comorbidity rates of the patient and control groups were
similar. For this reason, we consider that the effects of
chronic diseases such as diabetes for which it is possible
to see frequent malignity rates can be similar. We observed
that mass frequency increased depending upon an increase
in the GH level.
There are a large number of studies analysing malign
breast lesions in acromegaly patients. Within these studies,
a control group is included in two studies similar to our
study. These control groups are constituted of patients with
nonfunctional adenoma and prolactinoma.
Popovic et al. compared patients with acromegaly,
nonfunctional adenoma, and prolactinoma in their
published case-control study. Acromegaly patients had a
3.39-fold increased rate of malignity in general population.
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The rate of breast cancer incidence in acromegaly group
was found to be higher compared to the control group;
however, the difference was not statistically significant
[20]. In another case-control study published by Wolinski
et al., it was revealed that breast cancer is frequently seen
in the acromegaly group than the control group consisted
of patients with nonfunctional adenoma and prolactinoma
[21]. The association between acromegaly and breast
cancer frequency was not revealed clearly in studies
analysing only acromegaly patients.
In another study, no correlation could be found out
between IGF-1, GH levels and cancer in 445 acromegaly
patients. Furthermore, no increase has been found
out in breast cancer; however a poor correlation has
been detected between thyroid cancer frequency and
acromegaly. It is suggested that if studies correlated with
high IGF-1, GH levels, and high cancer incidence are
conducted through high-sensitive measures of today’s
technology, lower standardized incidence rate is detected
[22]. In a retrospective study analysing cancer incidence
and mortality in which 1362 acromegaly patients were
included, no increase in breast cancer was observed. In
addition to this, it was indicated that there was no increase
in mortality rate in malignant diseases, but colon cancer
mortality rate was higher than expected [23]. On the other
hand, Nabarro et al. revealed that there was a fourfold
increase in breast cancer incidence in acromegalic patients
[24]. An another study showed that there was a slight
increase in all cancer types including breast cancer [2].
An analysis of UK Biobank data showed that high IGF1 concentration in premenopausal and postmenopausal
females is associated with breast cancer risk increase
[25]. Guides for acromegaly patients’ management do
not include any scanning for breast tumors. Our data are
consistent with the instructions of the guides.
We compared our data to studies conducted in Turkey
in order to equalize ethnic and social factors in breast
cancer incidence in acromegaly patients. According to
Turkey cancer statistic 2015, the most common cancer
type is breast cancer in females in Turkey. (43,8/100.000
per person, Age Standardized Rate) According to a study
published by Dağdelen et al., breast cancer rate is 2.5% in
160 acromegaly patients [26] while this rate is 2.8% for 104
acromegaly patients with regard to the study conducted by
Güllü et al [27]. We detected breast cancer rate as 3.3% in
acromegaly patients and this rate was similar to previous
studies in Turkey.
Compared to acromegaly patients among themselves,
how patients in remission or not in remission have an effect
on the presence of breast lesions has not been proved.
As you realize, there are no study in literature
comparing benign breast lesions between acromegaly
patients in remission and not in remission. Güllü et al.

revealed that remission duration is significantly longer in
acromegaly patients with cancer diagnosis. No additional
information has been found out on breast cancer [27].
The strengths of our study are that all breast lesions
have not been evaluated in detail and our study has
a remarkable amount of controls. That our study is a
retrospective study and that data cannot be generalized
to acromegaly patients in the whole ethnic population
are the limitations of our study. Another limitation is that
radiology findings have not been evaluated by a single
expert because of the retrospective design.
As a consequence, according to our results, benign and
malign breast lesions in acromegaly patients were similar
to controls. Also, remission status of the patients appeared
not to have an effect on the progression of lesions. In
addition to them, we detected that breast density was
higher in acromegaly patients than the control group and
mass frequency increased depending upon an increase in
the GH level.
It should be kept in mind that increased breast density
and mass formation in breast increase breast cancer risk.
For this reason, patients should be regularly followed up
through suitable breast visualization techniques by taking
into consideration their age and clinical status.
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